The
daf-12 gene encodes a nuclear hormone receptor that integrates inputs from insulin/IGF, TGF- and cGMP signalling pathways and influences dauer formation, the heterochronic circuit and life span. Therefore, the set of
daf-12 target genes should be highly interesting. Shostak and Yamamoto (IWM, 2001) defined several putative DAF-12 DNA target sequences in the
lit-1 promotor by in vitro and in vivo experiments. We are searching for additional physiological candidate genes in identified signalling pathways. Surprisingly, one is
daf-9, a cytochrome P450 related to vertebrate steroidogenic hydroxylases. DAF-9 is thought to metabolize a DAF-12 hormone and acts by genetic epistasis experiments upstream of DAF-12. In contrast to this, we find that hypodermal
daf-9::gfp expression does not occur in
daf-12 null mutants, suggesting feedback regulation by DAF-12 (See abstract by Gerisch et al). Another candidate target is
let-7, a heterochronic gene coding for a small temporal RNA (stRNA) that regulates the larval to adult switch. Slack and Johnson (IWM, 2001) showed that a
let-7::gfp construct is temporally upregulated by the L4 stage in the same cell type as
daf-12::gfp. In addition,
daf-12 alleles with delayed heterochronic phenotypes, such as
rh61, also result in delayed or inhibited
let-7 expression (personal com. Slack et al). To investigate whether these candidates are directly regulated by DAF-12 in vivo, we are beginning chromatin immunoprecipitation (X-ChIP) experiments to define DNA regions to which the nuclear receptor binds. We will also dovetail these experiments with gel mobility shift assays using protein from nuclear extracts to narrow down the region of receptor binding and to identify corresponding response elements.